segunda-feira, dezembro 06, 2004
Resolução do Parlamento Europeu no Dia Mundial de Luta contra a Sida
The European Parliament,
- having regard to World AIDS Day on 1 December 2004 and its theme: Women, Girls and HIV/AIDS
- given the Commission Working Paper on a coordinated and integrated approach to combat HIV/AIDS within the EU and its neighbourhood,
- given the Dublin declaration on the Partnership to fight HIV/AIDS in Europe and Central Asia adopted in February 2004,
- given the June 2001 UN Declaration of Commitment on HIV/AIDS and the on-going UNAIDS programme,
- given the goal of a reduction of the contagion by 2015 set in the Millennium Declaration signed by the Heads of State and Government in September 2000
A. Whereas the totally number of people living with HIV/AIDS rose in 2004 in every region to reach an estimated level of 39.4 million with every increasing infection rates among women
B. Whereas, in 1997, 41% of HIV-positive people were women and girls, but today around half of all people living with HIV/AIDS world-wide are women and girls, and in sub-Saharan Africa the figure is 57%; and whereas so far there are 40 million people infected with HIV and approximately 90% of them are from developing countries
C. Whereas, in view of the gender inequalities associated with HIV/AIDS, finding vaccines that are available to women and young girls before the onset of sexual behaviour must be a budgetary and political priority; stresses that women must be involved in all appropriate clinical research, including vaccine trials
D. Whereas the proportion of newly reported HIV cases in Western Europe has doubled since 1995 with some of the highest rates of new infections to found in some of the new Member States and those third countries that share our Eastern border
E. Whereas increased investment in research and development with a view to more effective therapeutic and preventive medicines is vital to securing the long-term success of anti-HIV/AIDS action
F. Whereas it is crucial to promote safe sex practices and microbicides which are considered a promising prevention tool
G. Whereas sexual and reproductive health rights are intrinsically linked to the prevention of HIV/AIDS and other poverty diseases, and whereas the Millennium development goals (MDG) in general and those on promoting gender equality and empowering women, reducing child mortality, improving maternal health and combating HIV/AIDS in particular will only be achieved if sexual and reproductive health issues are put at the heart of the MDT's agenda
H. Whereas recent UNAIDS figures also point to increased levels of infection throughout the EU, particularly in the 15-25 age group
I. Whereas pharmaceutical companies must look at ways to reduce prices, since developing countries cannot afford the anti-viral drugs available in the industrialised world
J. Whereas in some countries HIV/AIDS- related costs will soon absorb over half the health budget
K. Whereas insufficient action against the HIV/AIDS epidemic could result in an unprecedented crisis, in particular in Southern Africa, undermining not only health and development but also national security and political stability in a number of countries
L. Whereas the WTO General Council adopted a waiver to article 31(f) of the TRIPS Agreement allowing WTO members to grant compulsory licences for manufacturing and distribution of patented pharmaceuticals intended for export to third countries with insufficient or no manufacturing capacity in the sector, which should increase the accessibility of low cost medicines in those countries
M. Whereas many developing countries will lose the possibility of producing generic medicines with the entry into force of TRIPS rules on 1 January 2005
1. Reaffirms the rights of every human being to have access to medical care and treatment
2. Recalls that if the trend of ever higher numbers of HIV-infected is not reversed, there will be no chance of achieving the overarching Millennium Development Goal, aimed at eradicating extreme poverty and hunger by 2015 and reducing by half the proportion of people living on less than a dollar a day and suffering from hunger
3. Stresses that the strategies needed to combat the HIV/AIDS epidemic effectively must include a comprehensive approach to prevention, education, care and treatment and must include the technologies currently in use, expanded access to treatment, as well as the urgent development of vaccines and microbicides
4. Is concerned also by the increasing rates of infections in some societies that do, a priori, have full access to all the necessary information about prevention and risk avoidance and in particular, in the 15-25 age group
5. Notes that the International AIDS Vaccine Initiative has drawn attention to the lack of funding from the private sector; calls therefore on private donors to join with charitable and public sectors to develop vaccines, especially in Africa
6. Calls on the EU and its Member States to dramatically increase funding for the development of microbicides, given that conservative estimates suggest that the introduction of even a partially effective microbicides would result in 2.5 million averted cases of HIV over 3 years, and that an effective microbicide could be development by the end of the decade with the necessary financial support
7. Stresses that access to medicines, including vaccines and diagnostic products, is a crucial importance, and that bringing down the costs of such treatment should be one of the priorities; therefore calls on the pharmaceutical industry to reduce prices
8. Calls on the Commission and the Member States to increase their commitments to research and development for more effective therapeutic and preventive medicines, in order to secure the long-term success of anti-HIV/AIDS action; in particular, calls on the EU and its Member States to mobilise additional funding to enable effective partnerships with the pharmaceutical companies for the development of vaccines
9. Notes with great interest the recent finding that a relatively cheap antibiotic (co-trimoxazole) has almost halved the rate of AIDS-related deaths in African children. Although the drug does not combat HIV, it is clearly instrumental in preventing secondary infections which kill many HIV-positive children with weakened immunity at an annual cost of just $7-12 per child compared to $300 for the cheapest antiretrovirals
10. Regrets that for many years in the past, prejudiced views in some sectors as regards the use of condoms prevented full and necessary attention being directed against HIV/AIDS
11. Calls on the United Nations and its Members to increase dramatically the visibility and prominence of sexual and reproductive health issues during the review of the Millennium Development Goals next year
12. Calls on the EU to continue to prioritise sexual and reproductive health issues through funding programmes on family planning, and in particular to influence sexual behaviour through risk-reduction strategies, to educate young people, and especially girls and young women, about STIs and HIV, and to encourage condom usage with other contraceptive methods and combat any misinformation spread on the effectiveness of condoms
13. Calls on the Commission to encourage developing countries to restore and develop public services in basic areas such as water access and sanitation, health and education
14. Stresses that HIV/AIDS cannot be dealt with in isolation and often goes hand in hand with other diseases such as tuberculosis, Hepatitis C, and mental disorders such as depression, and that care and treatment solutions need to be pursued for all these
15. Urges the Commission to create specific legislative instruments to encourage R&D on neglected and poverty diseases, and to ensure that the results of the research need the specific needs of developing countries and contribute towards a swift improvement in the public health situation
16. Calls on all involved partners to speed up measures for the authorisation of new drugs and vaccines and to ensure that patients in poorer European countries also have access to treatment at affordable prices
17. Regrets the lack of palliative care for those dying of AIDS and urges that the palliative care teams be trained and supported
18. Welcomes the Commission proposal setting up a uniform framework for issuing compulsory licences authorising production and exportation of cheaper medicines to the eligible countries in need
19. Insists on the importance of ensuring that the objective of providing developing countries with affordable medicines is not jeopardised by accessively restrictive or cumbersome procedures nor by re-importation into the European Union of pharmaceutical products manufactures under compulsory licences
20. Urges developed countries to adopt a waiver on the application of the TRIPS Agreement in this field so as to enable the pharmaceutical companies in developing countries to continue to provide generic low-cost medicines
21. Calls on the EU to develop policies and programmes in this area, and asks the Commission to ensure that increased resources are made available within the financial perspective for 2007-20013 to support a significant scaled up response to HIV/AIDS including by making a multi-annual commitment to the Global Fund against HIV/AIDS T.B. and Malaria
22. Firmly believes that the EU has a significant role to play for both its own citizens and those of third countries in the global fights against the disease. Welcomes in this respect the already existing EU funding for research projects, exchanges of best practice, the involvement of NGOs particularly those best placed to address the specific challenges faced by vulnerable groups such as immigrants, sex-workers etc.
23. Welcomes the decision by the UK, Sweden, and The Netherlands to agree to the request from many NGOs to make additional contributions to the Global Fund
24. Calls on the EU Member States, and particularly on the Italian Government, to respect their commitment to donate financial resources to the Global Fund and to ensure the continuation of all ongoing actions
25. Calls on the new Commission to ensure that funding continues to plug the "decency gap" left by the US withdrawal of UNFPA funding, not only in the developing world but also in Eastern Europe and Central Asia
26. Welcomes the Commission's statement of 23 November 2004 on the presentation in April 2005 of an action plan to fight AIDS and looks forward to concrete actions
27. Instructs its President to forward this resolution to the Council, the Commission, the Member States, the Co-presidents of the ACP-EU Joint Parliamentary Assembly, the WHO and UNAIDS
---------
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT ##by Agnoletto, Ilda Figueiredo, Morgantini on behalf of the GUE/NGL
Joint motion for a resolution by the AIDS-DAY
urges the Commission and the Member states to provide the Global Fund to Fight AIDS Tuberculosis and Malaria (GFATM) with contribution to at least up to 1 billion Euro on a sustained basis; recalls the commitment of the G8 and the rest of the international community to reach an overall target of annual expenditure between 7 and 10 billion;
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by _#Agnoletto, Ilda Figueiredo, Morgantini#_#on Behalf of the GUE/NGL ###Joint motion for a resolution by the AIDS-DAY
urges the European pharmaceutical industry to dedicate a significant part of its resources to anti-infectious medicines and other essential drugs; urges of example Sanofi-Aventis, the biggest European pharmaceutical group to take on research on this disease instead of disperse the team of researcher that has special knowledge on the matter
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by Agnoletto, Ilda Figueiredo, Morgantini on behalf of the GUE/NGL
Joint motion for a resolution by the AIDS-DAY
urges the Commission to work on a proposal in order to better safeguard the public interest in the orientation of research, development and production of medicines and encourage public research, development and production of drugs, in order to cut prices and reduce medical expenses for public health services and to guarantee the right of universal access to essential medical treatment and medicines;
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by Agnoletto, Ilda Figueiredo, Morgantini
Joint motion for a resolutionby the AIDS-DAY
urges the Commission to oppose both at the WTO level and in its bilateral relations, the inclusion by the United States in their bilateral agreement with developing countries of provisions that oblige those countries to renounce to the right recognised in the Doha declaration to use or import generic drugs necessary for the public health of its population; urges the EU to abstain itself from making any step in this same direction.
- having regard to World AIDS Day on 1 December 2004 and its theme: Women, Girls and HIV/AIDS
- given the Commission Working Paper on a coordinated and integrated approach to combat HIV/AIDS within the EU and its neighbourhood,
- given the Dublin declaration on the Partnership to fight HIV/AIDS in Europe and Central Asia adopted in February 2004,
- given the June 2001 UN Declaration of Commitment on HIV/AIDS and the on-going UNAIDS programme,
- given the goal of a reduction of the contagion by 2015 set in the Millennium Declaration signed by the Heads of State and Government in September 2000
A. Whereas the totally number of people living with HIV/AIDS rose in 2004 in every region to reach an estimated level of 39.4 million with every increasing infection rates among women
B. Whereas, in 1997, 41% of HIV-positive people were women and girls, but today around half of all people living with HIV/AIDS world-wide are women and girls, and in sub-Saharan Africa the figure is 57%; and whereas so far there are 40 million people infected with HIV and approximately 90% of them are from developing countries
C. Whereas, in view of the gender inequalities associated with HIV/AIDS, finding vaccines that are available to women and young girls before the onset of sexual behaviour must be a budgetary and political priority; stresses that women must be involved in all appropriate clinical research, including vaccine trials
D. Whereas the proportion of newly reported HIV cases in Western Europe has doubled since 1995 with some of the highest rates of new infections to found in some of the new Member States and those third countries that share our Eastern border
E. Whereas increased investment in research and development with a view to more effective therapeutic and preventive medicines is vital to securing the long-term success of anti-HIV/AIDS action
F. Whereas it is crucial to promote safe sex practices and microbicides which are considered a promising prevention tool
G. Whereas sexual and reproductive health rights are intrinsically linked to the prevention of HIV/AIDS and other poverty diseases, and whereas the Millennium development goals (MDG) in general and those on promoting gender equality and empowering women, reducing child mortality, improving maternal health and combating HIV/AIDS in particular will only be achieved if sexual and reproductive health issues are put at the heart of the MDT's agenda
H. Whereas recent UNAIDS figures also point to increased levels of infection throughout the EU, particularly in the 15-25 age group
I. Whereas pharmaceutical companies must look at ways to reduce prices, since developing countries cannot afford the anti-viral drugs available in the industrialised world
J. Whereas in some countries HIV/AIDS- related costs will soon absorb over half the health budget
K. Whereas insufficient action against the HIV/AIDS epidemic could result in an unprecedented crisis, in particular in Southern Africa, undermining not only health and development but also national security and political stability in a number of countries
L. Whereas the WTO General Council adopted a waiver to article 31(f) of the TRIPS Agreement allowing WTO members to grant compulsory licences for manufacturing and distribution of patented pharmaceuticals intended for export to third countries with insufficient or no manufacturing capacity in the sector, which should increase the accessibility of low cost medicines in those countries
M. Whereas many developing countries will lose the possibility of producing generic medicines with the entry into force of TRIPS rules on 1 January 2005
1. Reaffirms the rights of every human being to have access to medical care and treatment
2. Recalls that if the trend of ever higher numbers of HIV-infected is not reversed, there will be no chance of achieving the overarching Millennium Development Goal, aimed at eradicating extreme poverty and hunger by 2015 and reducing by half the proportion of people living on less than a dollar a day and suffering from hunger
3. Stresses that the strategies needed to combat the HIV/AIDS epidemic effectively must include a comprehensive approach to prevention, education, care and treatment and must include the technologies currently in use, expanded access to treatment, as well as the urgent development of vaccines and microbicides
4. Is concerned also by the increasing rates of infections in some societies that do, a priori, have full access to all the necessary information about prevention and risk avoidance and in particular, in the 15-25 age group
5. Notes that the International AIDS Vaccine Initiative has drawn attention to the lack of funding from the private sector; calls therefore on private donors to join with charitable and public sectors to develop vaccines, especially in Africa
6. Calls on the EU and its Member States to dramatically increase funding for the development of microbicides, given that conservative estimates suggest that the introduction of even a partially effective microbicides would result in 2.5 million averted cases of HIV over 3 years, and that an effective microbicide could be development by the end of the decade with the necessary financial support
7. Stresses that access to medicines, including vaccines and diagnostic products, is a crucial importance, and that bringing down the costs of such treatment should be one of the priorities; therefore calls on the pharmaceutical industry to reduce prices
8. Calls on the Commission and the Member States to increase their commitments to research and development for more effective therapeutic and preventive medicines, in order to secure the long-term success of anti-HIV/AIDS action; in particular, calls on the EU and its Member States to mobilise additional funding to enable effective partnerships with the pharmaceutical companies for the development of vaccines
9. Notes with great interest the recent finding that a relatively cheap antibiotic (co-trimoxazole) has almost halved the rate of AIDS-related deaths in African children. Although the drug does not combat HIV, it is clearly instrumental in preventing secondary infections which kill many HIV-positive children with weakened immunity at an annual cost of just $7-12 per child compared to $300 for the cheapest antiretrovirals
10. Regrets that for many years in the past, prejudiced views in some sectors as regards the use of condoms prevented full and necessary attention being directed against HIV/AIDS
11. Calls on the United Nations and its Members to increase dramatically the visibility and prominence of sexual and reproductive health issues during the review of the Millennium Development Goals next year
12. Calls on the EU to continue to prioritise sexual and reproductive health issues through funding programmes on family planning, and in particular to influence sexual behaviour through risk-reduction strategies, to educate young people, and especially girls and young women, about STIs and HIV, and to encourage condom usage with other contraceptive methods and combat any misinformation spread on the effectiveness of condoms
13. Calls on the Commission to encourage developing countries to restore and develop public services in basic areas such as water access and sanitation, health and education
14. Stresses that HIV/AIDS cannot be dealt with in isolation and often goes hand in hand with other diseases such as tuberculosis, Hepatitis C, and mental disorders such as depression, and that care and treatment solutions need to be pursued for all these
15. Urges the Commission to create specific legislative instruments to encourage R&D on neglected and poverty diseases, and to ensure that the results of the research need the specific needs of developing countries and contribute towards a swift improvement in the public health situation
16. Calls on all involved partners to speed up measures for the authorisation of new drugs and vaccines and to ensure that patients in poorer European countries also have access to treatment at affordable prices
17. Regrets the lack of palliative care for those dying of AIDS and urges that the palliative care teams be trained and supported
18. Welcomes the Commission proposal setting up a uniform framework for issuing compulsory licences authorising production and exportation of cheaper medicines to the eligible countries in need
19. Insists on the importance of ensuring that the objective of providing developing countries with affordable medicines is not jeopardised by accessively restrictive or cumbersome procedures nor by re-importation into the European Union of pharmaceutical products manufactures under compulsory licences
20. Urges developed countries to adopt a waiver on the application of the TRIPS Agreement in this field so as to enable the pharmaceutical companies in developing countries to continue to provide generic low-cost medicines
21. Calls on the EU to develop policies and programmes in this area, and asks the Commission to ensure that increased resources are made available within the financial perspective for 2007-20013 to support a significant scaled up response to HIV/AIDS including by making a multi-annual commitment to the Global Fund against HIV/AIDS T.B. and Malaria
22. Firmly believes that the EU has a significant role to play for both its own citizens and those of third countries in the global fights against the disease. Welcomes in this respect the already existing EU funding for research projects, exchanges of best practice, the involvement of NGOs particularly those best placed to address the specific challenges faced by vulnerable groups such as immigrants, sex-workers etc.
23. Welcomes the decision by the UK, Sweden, and The Netherlands to agree to the request from many NGOs to make additional contributions to the Global Fund
24. Calls on the EU Member States, and particularly on the Italian Government, to respect their commitment to donate financial resources to the Global Fund and to ensure the continuation of all ongoing actions
25. Calls on the new Commission to ensure that funding continues to plug the "decency gap" left by the US withdrawal of UNFPA funding, not only in the developing world but also in Eastern Europe and Central Asia
26. Welcomes the Commission's statement of 23 November 2004 on the presentation in April 2005 of an action plan to fight AIDS and looks forward to concrete actions
27. Instructs its President to forward this resolution to the Council, the Commission, the Member States, the Co-presidents of the ACP-EU Joint Parliamentary Assembly, the WHO and UNAIDS
---------
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT ##by Agnoletto, Ilda Figueiredo, Morgantini on behalf of the GUE/NGL
Joint motion for a resolution by the AIDS-DAY
urges the Commission and the Member states to provide the Global Fund to Fight AIDS Tuberculosis and Malaria (GFATM) with contribution to at least up to 1 billion Euro on a sustained basis; recalls the commitment of the G8 and the rest of the international community to reach an overall target of annual expenditure between 7 and 10 billion;
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by _#Agnoletto, Ilda Figueiredo, Morgantini#_#on Behalf of the GUE/NGL ###Joint motion for a resolution by the AIDS-DAY
urges the European pharmaceutical industry to dedicate a significant part of its resources to anti-infectious medicines and other essential drugs; urges of example Sanofi-Aventis, the biggest European pharmaceutical group to take on research on this disease instead of disperse the team of researcher that has special knowledge on the matter
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by Agnoletto, Ilda Figueiredo, Morgantini on behalf of the GUE/NGL
Joint motion for a resolution by the AIDS-DAY
urges the Commission to work on a proposal in order to better safeguard the public interest in the orientation of research, development and production of medicines and encourage public research, development and production of drugs, in order to cut prices and reduce medical expenses for public health services and to guarantee the right of universal access to essential medical treatment and medicines;
EUROPEAN PARLIAMENT
2004 2009
AMENDMENT by Agnoletto, Ilda Figueiredo, Morgantini
Joint motion for a resolutionby the AIDS-DAY
urges the Commission to oppose both at the WTO level and in its bilateral relations, the inclusion by the United States in their bilateral agreement with developing countries of provisions that oblige those countries to renounce to the right recognised in the Doha declaration to use or import generic drugs necessary for the public health of its population; urges the EU to abstain itself from making any step in this same direction.
